Why the study?
Does injectable trivalent poliovirus vaccine improve serologic responses compared to oral trivalent poliovirus vaccine in two-month-old children?
Does injectable trivalent poliovirus vaccine improve serologic responses compared to oral trivalent poliovirus vaccine in two-month-old children?
Injectable trivalent poliovirus vaccine produces significantly higher geometric mean titers against types 2 and 3 at 20 months of age compared to the oral vaccine.
Answers are grounded in this paper and cite their sources.
IPV supports durable seroprotection over OPV in infants; extends RCT evidence favoring injectable polio schedules.
United States children two months of age were randomly assigned to two groups that received either the commercially available oral trivalent poliovirus vaccine ( OPV ) or an injectable (inactivated) trivalent poliovirus vaccine (IPV) with a confirmed minimum D-antigen content of 27, 3.5, and 29 units for poliovirus types 1, 2, and 3, respectively. Vaccine was given at two, four, and 18 months of age. Sera obtained from 439 children at two, four, and six months of age and from 85 children at 18 and 20 months of age were examined for neutralizing antibodies. The percentage of children with detectable antibodies and the reciprocal geometric mean titers were similar for both groups at two months of age for antibodies to all three poliovirus types. At 20 months of age, all children but one had detectable antibodies to all three poliovirus types. Significantly higher geometric mean titers against types 2 and 3 were noted at 20 months of age for the IPV group.
No takes yet. Share an insight, caveat, or question.
McBean et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: